Belite Bio, Inc. (BLTE) Ownership
BLTE ownership summary
as of October 17, 2026- Institutions
- 24.3% of shares outstanding
- Insiders
- 43.65% of shares outstanding
- Shares outstanding
- 40.3M
- Float
- 19.6M shares available to trade
- Short interest
- 5.04% 1.1M shares short
- Days to cover
- 5.12 short interest up 0.7% vs prior month
- Institutions 24.27%
- Insiders 43.65%
- Other investors 32.09%
BLTE top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Darwin Global Management, Ltd. | 7.64% | 3.1M | $439.4M | +19,807 (+0.6%) | June 30, 2026 |
| 2 | Paradigm Biocapital Advisors LP | 3.06% | 1.2M | $176.0M | +118,093 (+10.6%) | June 30, 2026 |
| 3 | RTW INVESTMENTS, LLC | 1.78% | 715K | $102.1M | — | June 30, 2026 |
| 4 | Millennium Management LLC | 1.23% | 495K | $70.6M | −75,524 (−13.2%) | June 30, 2026 |
| 5 | Maverick Capital Ltd | 0.98% | 396K | $56.6M | +396,311 (0.0%) | June 30, 2026 |
| 6 | Eventide Asset Management, LLC | 0.97% | 391K | $55.8M | +33,179 (+9.3%) | June 30, 2026 |
| 7 | Deerfield Management Co | 0.89% | 357K | $51.0M | +53,186 (+17.5%) | June 30, 2026 |
| 8 | Holocene Advisors, LP | 0.62% | 251K | $35.8M | −243,460 (−49.2%) | June 30, 2026 |
| 9 | Logos Global Management LP | 0.62% | 250K | $35.7M | +250,000 (0.0%) | June 30, 2026 |
| 10 | Morgan Stanley - Brokerage Accounts | 0.58% | 235K | $33.6M | +33,662 (+16.7%) | June 30, 2026 |
| 11 | UBS Group AG | 0.56% | 225K | $32.1M | −543,370 (−70.7%) | June 30, 2026 |
| 12 | Citadel Advisors Llc | 0.46% | 186K | $26.6M | +184,160 (+9,171.3%) | June 30, 2026 |
| 13 | The Goldman Sachs Group Inc | 0.41% | 166K | $23.7M | +60,679 (+57.5%) | June 30, 2026 |
| 14 | Affinity Asset Advisors, LLC | 0.41% | 165K | $23.6M | +100,000 (+153.8%) | June 30, 2026 |
| 15 | MPM Oncology Impact Management LP | 0.34% | 137K | $19.6M | +49,163 (+55.8%) | June 30, 2026 |
| 16 | Bank of America Corp | 0.31% | 125K | $17.8M | +121,005 (+3,202.9%) | June 30, 2026 |
| 17 | Patient Square Capital LP | 0.27% | 110K | $15.7M | −6,684 (−5.7%) | June 30, 2026 |
| 18 | Duquesne Family Office LLC | 0.26% | 106K | $15.1M | — | June 30, 2026 |
| 19 | T. Rowe Price Associates, Inc. | 0.26% | 106K | $15.1M | −175,946 (−62.4%) | June 30, 2026 |
| 20 | Jane Street Group LLC | 0.16% | 66K | $9.4M | +53,579 (+438.4%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 1.5M shares and 5 cut 1.0M.
BLTE top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Eventide Healthcare & Life Sciences I | 0.97% | 391K | $55.8M | +33,179 (+9.3%) | June 30, 2026 |
| 2 | MEDICAL BioHealth EUR Acc | 0.20% | 81K | $11.6M | −16,585 (−17.0%) | August 31, 2026 |
| 3 | HBM Healthcare Investments AG Ord | 0.10% | 40K | $5.7M | −39,134 (−49.6%) | June 30, 2026 |
| 4 | State Street® SPDR® Portfolio EM ETF | 0.07% | 30K | $4.3M | — | September 30, 2026 |
| 5 | apo Medical Opportunities R | 0.05% | 22K | $3.1M | — | August 31, 2026 |
| 6 | Biotech Growth Ord | 0.03% | 13K | $1.9M | — | June 30, 2026 |
| 7 | RIM Global Bioscience EUR | 0.03% | 13K | $1.8M | — | June 30, 2026 |
| 8 | Fidelity Nasdaq Composite Index | 0.02% | 6,727 | $960,481 | — | August 31, 2026 |
| 9 | TD Health Sciences - I | 0.02% | 6,505 | $928,784 | −2,400 (−27.0%) | June 30, 2026 |
| 10 | Fidelity ZERO International Index | 0.01% | 5,934 | $847,257 | — | August 31, 2026 |
| 11 | ActivePassive International Equity ETF | 0.01% | 4,286 | $611,955 | — | September 30, 2026 |
| 12 | Fidelity Nasdaq Composite ETF | 0.01% | 3,745 | $534,711 | — | September 30, 2026 |
| 13 | State Street® SPDR® S&P® China ETF | 0.01% | 3,192 | $455,754 | — | September 30, 2026 |
| 14 | Fidelity Select Biotechnology | 0.01% | 3,100 | $442,618 | — | August 31, 2026 |
| 15 | Virtus LifeSci Biotech Clinical Trls ETF | 0.01% | 2,297 | $327,966 | — | September 30, 2026 |
| 16 | Fidelity Flex International Index | 0.01% | 2,090 | $298,410 | — | August 31, 2026 |
| 17 | JHVIT Health Sciences I | <0.01% | 1,682 | $240,156 | −431 (−20.4%) | August 31, 2026 |
| 18 | Even Herd Long Short ETF | <0.01% | 1,297 | $185,186 | — | September 30, 2026 |
| 19 | EQ/T. Rowe Price Health Sciences IB | <0.01% | 1,200 | $171,336 | −200 (−14.3%) | August 31, 2026 |
| 20 | ProFunds UltraChina Inv | <0.01% | 1,030 | $147,063 | +74 (+7.7%) | July 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
BLTE insider transactions
latest 7| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | Nathan L Mata | Sell | $170.38 | 1,000 | $170,380 |
| 2026-04-20 | Nathan L Mata | Sell | $163.59 | 1,000 | $163,590 |
| 2026-04-17 | Nathan L Mata | Sell | $161.63 | 1,000 | $161,630 |
| 2026-04-15 | Nathan L Mata | Sell | $168.30 | 1,000 | $168,300 |
| 2026-04-09 | Hao-Yuan Chuang | Sell | $181.50 | 6,200 | $1.1M |
| 2026-04-09 | Wan-Shan Chen | Sell | $180.43 | 1,100 | $198,473 |
| 2026-04-09 | Yu-Hsin Lin | Sell | $181.45 | 9,200 | $1.7M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
BLTE shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns BLTE
Institutional investors own 24.3% of Belite Bio's shares and insiders 43.65%. The largest holder is Darwin Global Management, Ltd. with 7.64% of the shares (3.1M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 5 reduced their stake in the latest filings. Short interest is 5.04% of the float, or 5.12 days of average trading volume. The share count rose 279.2% since 2020.
Related: BLTE analyst forecast, BLTE key metrics. See the BLTE stock overview for the latest quote and news.
BLTE ownership FAQ
Who owns the most Belite Bio stock?
The largest shareholders of Belite Bio are Darwin Global Management, Ltd. (7.64%), Paradigm Biocapital Advisors LP (3.06%), RTW INVESTMENTS, LLC (1.78%), Millennium Management LLC (1.23%), Maverick Capital Ltd (0.98%).
What percentage of Belite Bio is owned by institutions?
Institutions hold 24.3% of Belite Bio's shares outstanding; insiders hold 43.65%.
Which funds own Belite Bio?
The largest fund holders of Belite Bio are Eventide Healthcare & Life Sciences I (0.97%), MEDICAL BioHealth EUR Acc (0.20%), HBM Healthcare Investments AG Ord (0.10%), State Street® SPDR® Portfolio EM ETF (0.07%), apo Medical Opportunities R (0.05%).
What is Belite Bio's short interest?
1.1M shares of Belite Bio were sold short, 5.04% of the float; at the average daily volume it would take 5.12 days to cover.
Are insiders buying or selling Belite Bio?
Of the latest 7 reported insider transactions in Belite Bio (since April 9, 2026), 0 were purchases and 7 were sales.
How many shares of Belite Bio are outstanding?
Belite Bio has 40.3M shares outstanding, of which 19.6M are in the public float.